Eupraxia Pharmaceuticals Inc. SEC filings EPRX

Eupraxia Pharmaceuticals Inc. has 126 filings in SEC EDGAR's recent list, going back to Jul 11, 2013. Its latest annual report, Form 40-F, was filed on Mar 13, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 22, 2026. The company's fiscal year ends on December 31.

Eupraxia Pharmaceuticals Inc. SEC filings
Form Description Filed Period
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 13, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 12, 2026 —
SCHEDULE 13D/A Amended ownership over 5% (active) Mar 16, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 17, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Nov 14, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Nov 13, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Sep 26, 2025 —
SC 13G Ownership over 5% (passive) Nov 14, 2024 —
SC 13D Ownership over 5% (active) Nov 7, 2024 —

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
EPRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
British Columbia, Canada
Headquarters
Vancouver
SEC filer status
, Emerging growth company
SEC CIK
1581178

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.